544 reports of this reaction
2.1% of all RITONAVIR 100 MG reports
#7 most reported adverse reaction
OFF LABEL USE is the #7 most commonly reported adverse reaction for RITONAVIR 100 MG, manufactured by Cipla USA Inc.. There are 544 FDA adverse event reports linking RITONAVIR 100 MG to OFF LABEL USE. This represents approximately 2.1% of all 25,519 adverse event reports for this drug.
Patients taking RITONAVIR 100 MG who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for RITONAVIR 100 MG, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for RITONAVIR 100 MG:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 544 FDA reports for RITONAVIR 100 MG. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.1% of all adverse event reports for RITONAVIR 100 MG, making it a notable side effect.
If you experience off label use while taking RITONAVIR 100 MG, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.